News

According to Nicox SA, the patients made their final 3-month visit last week. Topline results of the trial are expected in November.

Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.

Researchers found that the rate of visual decline increased significantly in patients with age-related macular degeneration during the COVID-19 lockdown who were followed over time.

Elizabeth Yeu, MD, will highlight pearls for managing intraocular lenses in difficult cases.

A poll for retina specialists regarding their attendance at the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois. The poll is now closed.

The Eye Center at UC Davis Health has two new endowed chairs focused on glaucoma, thanks to a $4 million donation from business entrepreneur Daryl Geweke.

Ophthalmologists should instruct their patients to pay attention to their eye health for the long term.

In AMD research, the experimental animals used are often young male mice. This is not optimal for the development of new treatments, as the disease most often affects the elderly – and women.

Cataract density and the fragmentation pattern the surgeon uses may influence the amount of ultrasound energy used for phacoemulsification and EPT.

Claes H. Dohlman, MD, PhD, widely considered the father of modern cornea science, is a recipient of the 2022 António Champalimaud Vision Award. The award, considered the “Nobel Prize of Vision," comes with a $1 million prize .

According to Rishi P. Singh, MD, family history and lifestyle are key in the development of geographic atrophy.

Researchers found that the rate of visual decline increased significantly in patients with age-related macular degeneration (AMD) during the COVID-19 lockdown who were followed over time.

LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.

How long-term intravitreal steroid technology fits into a modern clinic.

Heru debuts dark adaptation, the newest modality added to its wearable health and wellness platform’s vision screening line-up.

Medication is administered after LASIK and injectable prophylaxis during cataract surgery.

Members of the Ophthalmology Times Europe Editorial Advisory Board offer comments on the symposia they are most excited to attend at the 2022 ESCRS Congress in Milan, Italy.

No one should ever have to choose between quality health care and preserving money, especially for those we love or for ourselves.

Sigma extends access to powerful no-code cloudscale data analytics for industry-compliant data cloud so healthcare professionals and researchers can find faster answers to critical questions.

The American Academy of Ophthalmology annual meeting is coming to Chicago, Illinois, from September 30 to October 3, featuring Subspecialty Days and a virtual component.

Spanish investigators hypothesise that conjunctivitis plays a role in disease transmission.

Nanoscope Therapeutics’ Phase 2 STARLIGHT open-label trial enrolled 6 subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.

This method of administration facilitates targeted delivery of the medication to the retina and choroid.

The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and increased patient sensitivity to medication costs.

The ScoutPro system allows eye care practices to minimize tech time and seamlessly integrate osmolarity testing into any practice configuration or patient protocol.